55662-66-3

Usage

InChI:InChI=1/C6H7N3O/c10-6-8-2-1-5-7-3-4-9(5)6/h1-5,7H,(H,8,10)

Upstream product

• 71-30-7 Cytosine 
• 19263-02-6 2-bromomalondialdehyde 
• 56860-78-7 bromoacetaldehyde hydrate 
• 107-20-0 2-chloroethanal 
• 65-46-3 CYTIDINE 
• 55662-54-9 2-chloro-N-(2,2-diethoxyethyl)pyrimidin-4-amine 

Downstream Products

• 68498-26-0 3,N⁴-etheno-2'-deoxycytidine (5,6-dihydro)-5-oxo-6-(β-D-2'-deoxyribofuranosyl)imidazol[1,2-c]pyrimidine 

Relevant academic research and scientific papers

Analysis of 3,N4-ethenocytosine in DNA and in human urine by isotope dilution gas chromatography/negative ion chemical ionization/mass spectrometry

The promutagenic etheno DNA adducts have been detected in tissue DNA of rodents and humans from various exogenous and endogenous sources. While other etheno DNA adducts have been detected and quantified by isotope dilution gas chromatography/negative ion chemical ionization/mass spectrometry (GC/NICI/MS), similar analysis for 3,N4-ethenocytosine (εCyt) has not been available. In this report, a GC/NICI/MS assay was developed for detection and quantification of εCyt in DNA and in human urine samples. The stable isotope of εCyt with 7 mass units higher than the normal εCyt was synthesized and used as internal standard of the assay. The adduct-enriched fraction of DNA hydrolysate was derivatized with pentafluorobenzyl bromide before GC/NICI/MS analysis with selective ion monitoring at [M - 181]- fragments of pentafluorobenzylated εCyt and its isotope analogue. One femtogram (S/N > 40) of pentafluorobenzylated εCyt was detected when injected on column with selective ion monitoring mode. The limit of quantification for the entire assay was 7.4 fmol of εCyt, which was approximately one thousand times lower than that of the HPLC/fluoreseence assay for the nucleoside 3,N4-etheno-2′-deoxycytidine in DNA. Analysis of chloroacetaldehyde-treated calf thymus DNA by both GC/NICI/MS and HPLC/fluorescence methods provided similar adduct levels and thus verified the assay. This GC/NICI/MS method was used for analysis of εCyt in two smokers' urine samples and the average level of εCyt was 101 ± 17 pg/mL/g of creatinine. Thus, quantification of εCyt in DNA and in urine by this highly specific and ultrasensitive isotope dilution GC/NICI/MS assay may facilitate research on the role of εCyt in carcinogenesis and in cancer development.

Cyclic dinucleotide analogues, pharmaceutical composition of analogues and applications of analogues and pharmaceutical composition

The invention discloses cyclic dinucleotide analogues, a pharmaceutical composition of the analogues and applications of the analogues and the pharmaceutical composition. The cyclic dinucleotide analogs (I), an isomer, prodrug, stable isotope derivative or pharmaceutically acceptable salt of the analogs have a structure shown in the specification. The cyclic dinucleotide analogs provided by the invention can be used as regulators of stimulator of interferon genes (STIG) and related signaling pathways, and can effectively treat and/or alleviate multiple types of diseases, including but not limited to malignant tumors, inflammation, autoimmune diseases and infectious diseases; and in addition, the STING regulators can also be used as vaccine adjuvants.

HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.

NOVEL FUSED PYRIMIDINONE AND TRIAZINONE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES AS ANTIFUNGAL AND/OR ANTIPARASITIC AGENTS

The present invention concerns novel fused pyrimidinone and triazinone derivatives of formula (I), their process of preparation and their use as antifungal or antiparasitic agents.

Synthesis, structure and rearrangement of iodinated imidazo[1,2-c]pyrimidine-5(6H)-ones derived from cytosine

We describe mild and selective iodination of various 8-substituted imidazo[1,2-c]pyrimidine-5(6H)-ones (ethenocytosines). Starting ethenocytosines were obtained by cyclization of 5-halogenocytosines with chloroacetaldehyde or by subsequent Suzuki-Miyaura

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Structural Alteration of Nucleic Acid Bases by Bromomalonaldehyde

Bromomalonaldehyde (BMDA), prepared by bromination of malonaldehyde with elemental bromine, has been employed to modify a number of nucleic acid bases.These reactions transform pyrimidine and purine bases into modified systems containing etheno and etheno carboxaldehyde moieties, among other products.The structures of these modified bases were established by UV, mass spectral, and high-field NMR data.Fluorescence emission data for some of the adducts are of significance.The general mechanism of modification is discussed.